RedHill Biopharma Ltd. ADR (RDHL)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes
On Monday, RedHill Biopharma Ltd. RDHL released results from multiple in vivo studies, undertaken by RedHill's partner, Apogee Biotechnology Corporation.
Why Is RedHill Biopharma (RDHL) Stock Up 75% Today?
One of today's biggest movers in the biotech sector is RedHill Biopharma (NASDAQ: RDHL ), a little-known specialty player in the space focusing on gastrointestinal and infectious diseases. Today, RDHL stock is up more than 75% in early afternoon trading on an announcement from the company that it has seen positive results for a key Phase 3 study.
RedHill Biopharma Ltd. ADR (RDHL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has RedHill Biopharma Ltd. ADR ever had a stock split?
RedHill Biopharma Ltd. ADR Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Dror Ben-Asher CEO | NASDAQ (CM) Exchange | 757468103 CUSIP |
| IL Country | 35 Employees | - Last Dividend | 20 Aug 2024 Last Split | - IPO Date |
Overview
RedHill Biopharma Ltd. is a specialty biopharmaceutical company with a primary focus on developing treatments for gastrointestinal and infectious diseases. Founded in 2009 and based in Tel Aviv, Israel, the company seeks to advance its portfolio through the development and commercialization of novel therapeutic candidates. RedHill's commitment to addressing unmet medical needs in these domains is exemplified by its innovative pipeline, which includes treatments aimed at combating severe medical conditions such as COVID-19 pneumonia and Crohn's disease.
Products and Services
- Talicia - Developed for the treatment of H. pylori infection in adults, an infection strongly associated with peptic ulcer disease and some types of gastric cancer.
- Aemcolo - A treatment option for travelers' diarrhea in adults, addressing a common affliction that affects millions of international travelers each year.
- Opaganib - This therapeutic candidate is in the pipeline for multiple serious conditions, including patients hospitalized with severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and as protection against nuclear radiation.
- RHB-107 (Upamostat) - Focused on treating outpatients infected with SARS-CoV-2, the virus responsible for COVID-19 disease, as well as advanced unresectable cholangiocarcinoma, a type of bile duct cancer.
- RHB-104 - A potential treatment for Crohn's disease, a chronic inflammatory bowel disease that affects the lining of the digestive tract.
- RHB-102 (Bekinda) - Aimed at addressing acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea (IBS-D), and serving as an anti-emetic in oncology support.
- RHB-204 - A proposed solution for pulmonary nontuberculous mycobacteria infections caused by Mycobacterium avium complex, a condition that can lead to severe lung disease.
Contact Information
